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Abstract 
 
Cancer cells show a metabolic shift that makes them overproduce protons; this has the 
potential to disturb the cellular acid-base homeostasis. However, these cells show 
cytoplasmic alkalinisation, increased acid extrusion and endosome-dependent drug 
resistance. Vacuolar type ATPases (V-ATPases), toghether with other transporters, are 
responsible to a great extent for these symptoms. These multisubunit proton pumps are 
involved in the control of cytosolic pH and the generation of proton gradients (positive 
inside) across endocellular membrane systems like Golgi, endosomes or lysosomes. In 
addition, in tumours, they have been determined to play an important role in the 
acidification of the intercellular medium. This importance makes them an attractive target 
for control of tumour cells. In the present review we portray the major characteristics of 
this kind of proton pumps, we provide some recent insights on their in vivo regulation, an 
overview of the consequences that V-ATPase inhibition carries for the tumour cell, such as 
cell cycle arrest or cell death, and a brief summary of the studies related to cancer made 
recently with commercially available inhibitors for this kind of proton pump. Some new 
approaches to affect V-ATPase function are also suggested in the light of recent 
knowledge on the regulation of this proton pump. 
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In tumor cells, NADH is recycled to its oxidised form by reducing pyruvate to lactic acid, 
instead of being transported to and being processed at the mitochondria. As a consequence, 
two H+ per glucose molecule consumed are released into the cytosol and need to be 
disposed of in order to maintain cytosolic pH homeostasis. Strikingly, tumour cells not 
only maintain a near-neutral pH, but they often display a slightly alkaline cytosol in 
comparison to normal cells, probably as an acquired advantage against apoptosis induction 
[1]. The most obvious way to dispose of H+ is to extrude them to the intercellular space. 
This has some added advantages for the tumour cell: lactate and H+ are immunosuppresors 
that impair cytotoxic T lymphocyte metabolism [2]. Moreover, an acid external medium 
promotes invasion and cell proliferation by providing the optimal conditions for proteases 
like cathepsins or matrix metalloproteases that can degrade the intercellular matrix and 
promote angiogenesis [3] and even help the scape of highly proliferating or metastatic cells 
from the tumour into adjacent tissues or the blood stream [4]. All this, together with the 
fact that solid tumours typically display deficient perfusion, especially at the inner core, 
complicates cytosolic homeostasis because steep H+ gradients need to be maintained across 
the plasma membrane of neoplastic cells in order to keep H+ from flooding back into the 
cytoplasm. V-ATPases represent the sole primary H+ transporters in endosomes, Golgi 
cisternae and lysosomes in mammalian cells. In other organisms, such as parasitic 
trypanosomatids –responsible for diseases like malaria, Kala azar, sleeping sickness or 
chagas disease- H+-pumping pyrophosphatases comprise a second set of pumps and may 
be an important pharmacological target to fight these ailments [5, 6]. V-ATPases are 
usually absent from the cell surface, but it is naturally located at the plasma membrane of 
some cell types such as those at the vas deferens and in osteocytes [7, 8]. In tumour cells, 
its presence at the plasma membrane has been reported [9, 10]. How this location is 
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achieved by a usually intracellular protein is still obscure, but examples of other proteins 
of similar origin being found in the extracellular environment are known in neoplasic cells, 
e.g. the cathepsins [11]. It is thought that plasmalemmal V-ATPases play a significant role 
in proton extrusion and regulation of cytosolic pH in mammalian cells [12]. At any rate, 
plasma membrane V-ATPase abundance have been shown to correlate with metastatic and 
proliferative potential [9, 12].  
 
ACIDIFICATION OF INTERNAL CELL COMPARTMENTS 
 
An overproduction of acid equivalents also has implications in internal organelles since 
many of them maintain pH values in their lumina that need to differ substantially from that 
of the cytoplasm. Under physiological conditions, maintenance of these proton gradients 
has been found to be necessary for vacuole fusion [13], glycosylation of proteins in the 
Golgi apparatus [14, 15], ligand-receptor dissociation and recycling in endosomes [16], 
endosomal proteolysis of ligands [17], and protein transport from endosomes to lysosomes 
[18]. In addition, drug sequestration is also dependent on the maintenance of lysosomal 
acidification [19]. The endo and exocytic pathways transport cargo and vesicles between 
different organelles (Fig. 1). As a gross simplification, it could be considered that the 
endoplasmic reticulum (ER) lies at one end of these pathways, while the lysosome and the 
plasma membrane would represent the other end. The ER maintains no pH difference 
compared with that of the cytosol. However, the closer we move towards the lysosome and 
the plasma membrane, H+ gradients (acid inside) maintained in the lumina of the different 
organelles become steeper (Fig. 1).  
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It must be noted that, although V-ATPases are the primary pumps driving the 
accumulation of protons inside single-membrane organelles, the final proton gradient 
formed is the result of the interaction of several other factors playing in favour or against 
the build up of such a gradient. For example, biological membranes are, to some extent, 
permeable to protons; also, secondary transporters consume accumulated protons to drive 
the translocation of substrates such as Na+ or amino acids. Conversely, the action of 
channels that dissipate the electrical gradient associated to the accumulation of positive 
charges (e.g. Cl- channels) allow a greater accumulation of H+. In addition, resident 
proteins and solutes with (de)protonable residues provide buffering capacity to organelle 
lumina. For a detailed view on the determinants acting on these organelles, the reader may 
refer to more specialised reviews [20, 21]. Although an intervention on any of these factors 
should produce an alteration of luminal pH, many of these are difficult to target and the 
extent of the individual importance of some others is still unknown. Hence V-ATPase 
reveals itself as the best candidate for pharmacological intervention to affect luminal 
acidification. 
 
STRUCTURE OF V-ATPASES 
 
These H+-pumps are complex multisubunit enzymes capable of coupling the hydrolysis of 
ATP or, with a much lower affinity, GTP to the translocation of H+ across a membrane 
[22]. Its name derives from being first identified at the plant vacuolar membrane as a H+-
pump different to those found in mitochondria and plasma membrane (F0F1 and P-type 
ATPases, respectively). All in all, the fully assembled mammalian holoenzyme displays a 
molecular mass nearing 900 kDa. 
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The V-ATPase was early observed to share some structural homology with the F0F1 
ATPase of mitochondria and bacteria [23] and thus, much of its domain nomenclature is 
influenced by knowledge on the mitochondrial pump. Indeed it is considered likely that 
these two types of ATPases share a common ancestor that behaved as an ATP synthase, 
probably akin to that found in present archaea [24]. Similarly to bacterial and 
mitochondrial transporters, V-ATPases are composed of two different multisubunit 
domains: one composed of lipophylic polypeptides and the other by hydrophylic proteins. 
The hydrophylic domain, named V1 by similarity to the F1 domain in F0F1 ATPases, is 
composed by eight different polypeptides (termed always using capital letters, A to H) 
(Fig. 2). The stoichiometry of these polypeptides is three for A, B, E and G and one for C, 
D, H, and F. Polypeptides A and B form an hexamer complex alternating A’s with B’s; 
single components attach to this substructure and to each other mostly on the V0-proximal 
side. On their turn, polypeptides E and G extend their physical interaction further up to 
provide a bridge between the V1 domain and RAVE complexes involved in regulation of 
V0/V1 assembly [25]. On its turn, the V0 domain consists of a ring composed of five c 
subunits and a single c’’ one. In close contact with this, there are single copies of a, d and e 
subunits and, in the case of mammals, an accessory subunit termed Ac45. This last subunit 
may be specific of plasma membrane localised pumps [26]. 
Subunits A in the V1 domain have ATPase hydrolytic activity and, since subunits B 
immobilise the V1 domain through their interaction with the actin cytoskeleton [27, 28], 
the free energy released in these reactions is transmitted, with the help of subunitis Dfd, to 
the cc'' subunit ring providing torque for the rotation of the latter [29]. Noteworthy, 
subunits C, E, G, H, in the V1 domain, and subunit a in the V0 domain remain static 
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through its physical interaction with the A3B3 hexamer. This is important because subunit a 
contains two hydrophylic hemichannels. The first one feeds H+ from the external side of 
the membrane to the c and c’’ subunits. Protons are bound by glutamic acid residues in the 
core of these polypeptides and kept for a full turn with the help of the hydrophobic 
environment of the membrane until the loaded subunit c or c’’ reaches back subunit a and 
comes in contact with the second hemichannel. This second hemichannel permits the exit 
of the H+ from the luminal side of the membrane. Typically, V-ATPase rotors turn 
clockwise, as seen from the normal to the cytosolic plane of the membrane, and, in a single 
360o rotation, up to two H+ are translocated per ATP consumed [29]. However, actual H+ 
stoichiometry depends on the isoform of subunit a that integrates the pump. Thus, in 
budding yeast, Stv1p isoform generates pumps that translocate a single H+ per ATP 
consumed, while Vph1p harbouring V-ATPases conform to the theoretical 2 H+/ATP [30]. 
The implications of this in V-ATPase regulation will be dealt with farther on. 
 
REGULATION OF V-ATPASE ACTIVITY 
 
Knowledge on regulation of V-ATPase activity has received a boost recently. The best 
characterised mechanism of its H+-pumping activity regulation is by assembly/dissasembly 
of the holoenzyme. Under physiological conditions, domains V0 and V1 are devoid of H+ 
transport or ATP hydrolytic activity, respectively, when not as part of the holoenzyme [31, 
32]. This makes possible to use assembly of the pump as a comparatively simple 
mechanism to regulate dynamically the total H+ transport capacity on the envelope of an 
organelle. Domain V0 is synthesized and assembled in the ER and transported to the Golgi 
system via COP II coated vesicles where it will receive a V1 domain already assembled in 
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the cytosol [33]. However, this holoenzyme can disassemble and reassemble V1 and V0 
domains in response to cell energy status. In yeast, it was early shown that vacuolar V-
ATPases rapidly disassembled upon glucose deprivation but that it could reassemble when 
the sugar was added back to the growth medium [34]. This same behaviour has been 
observed in renal epithelial cells [35, 36] and, probably, it plays a role in other tissues, as it 
is suggested by the results reported on ovine rumen [37]. The first indication of a 
regulatory link between carbohydrate metabolism and reversible assembly of this H+-pump 
came from osteoclasts and kidney cells, where aldolase was identified as a an interacting 
partner with subunit E influencing the assembly of the holoenzyme [38]. Later it was 
determined that the enzymatic activity of aldolase was not required for its regulatory 
function [39]. Anyhow, this behaviour has been best studied in budding yeast and much of 
the following information comes from this model organism. Noteworthy, the mechanisms 
for assembly and disassembly are different: while disassembly requires an intact tubulin 
microtubular network, reassembly of the holoenzyme depends on RAVE (regulator of the 
H+-ATPase of vacuolar and endosomal membranes), a protein complex that interact with 
subunits E, G and C and maintains them in an assembly-competent state [40]. In yeast, 
reversible (re)assembly of the holoenzyme has been proposed to derive from 
ras/cAMP/PKA pathway activation [41]. According to this model, intracellular glucose 
would activate the ras pathway leading to PKA activation through an increase in cAMP 
[41]. How PKA could be exerting its influence on assembly is still not clear; work by Voss 
et al. has shown a direct phosphorylation of subunit C by PKA that could influence V1/V0 
assembly [42, 43]. In line with this, PKA has already been reported to phosphorylate the 
catalytic subunit A and regulate V-ATPase activity in human kidney cells [44], although 
no data on dissociation of the complex was reported in this case. Related to this, AMPK 
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(AMP-activated protein kinase) could be exerting an inhibitory role, opposed to  activation 
by PKA, in kidney epidydimal cells [45, 46]; however, in this report AMPK would be 
affecting the H+-pump distribution rather than assembly. Alternatively, at least in yeast, 
glucose metabolism, or to be more exact, a high glycolytic flux, would translate into an 
increased cytosolic pH that could be sensed by V-ATPases through yet obscure 
mechanisms and this would drive their reassembly; activation of PKA would result as a 
downstream effect of the reactivation of H+ transport [47]. This is in agreement with 
subunit a being proposed as a pH sensor for the holoenzyme, both in yeast and in kidney 
epithelial cells [48-50]. Further work is needed to clarify the involvement of PKA in 
reassembly. It would be interesting to ascertain if this kinase shows any effect on RAVE. 
Nevertheless, extracellular pH has been shown to affect the ability of yeast V-ATPases to 
reversibly dissociate their V1 and V0 domains [51], although in this case cytosolic pH was 
shown not to be altered. In addition to this, other signalling pathways may also be 
contributing to the regulation of V-ATPases. In proximal tubule and kidney cells, PI3-
kinase has been reported to activate V-ATPase activity and assembly [35, 36, 52], and in 
the former type of cells, angiotensin II could be exerting an activation of the enzyme 
through both PI3K and p38MAPK [53]. Other protein kinases, such as analogs of the yeast 
stress and cell-cycle related Dbf2p [54], may prove important for V-ATPase activity and 
assembly in mammalian cells in the future. 
 
Regulation of gene expression is a commonly encountered mechanism for enzyme activity 
regulation. However, as it is easily understandable for a multisubunit complex that is 
composed of at least 13 different polypeptides, the concerted gene regulation of all of them 
is cumbersome. In agreement with this, early studies supported the notion that V-ATPases 
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were housekeeping proteins. Promoters corresponding to isoforms of proteins A, B and c 
from Neurospora crassa showed no recognisable TATA boxes and a high G+C content, 
characteristics associated to other known housekeeping genes [55]. However, as it was 
noted already by then, some subunit B isoforms in human macrophages and in the tobacco 
hornworm Manduca sexta showed indications in their promoters of being inducible. 
Advances in this field have been sparing and, for the most part, there is little detailed 
knowledge on inducibility of other isoforms and subunits. However, overexpression of 
subunits C and c have been found in the context of cancer: it has been shown that 
ATP6V1C1 human gene (encoding subunit C) is overexpressed in oral squamous 
carcinoma cells and that this may promote a greater degree of V1V0 assembly than in 
normal tissue [56]. Similarly, different subunit genes have been found to be overexpressed 
in drug-resistant cell lines, including ATP6L (ATP6V0C, subunit c) in the case of cisplatin 
resistance [57]. Remarkably, it has been reported recently that active mTORC1 induces the 
expression of genes encoding several V-ATPase subunits, including isoforms for subunits 
A, B, C, G, c and c'', through TEFB transcription factor in both human cells and mice [58].  
Differential expression of subunit isoforms is another way of accomplishing regulation. A 
thorough recollection can be found in an excellent review published recently [40]. Thus, 
we will be only give a few hints here. In particular, subunit a isoforms dictate to a large 
extent the location of the full complex. In yeast, all subunits are encoded by single genes 
with the exception of subunit a. Assembled complex containing the isoform Vph1p are 
located exclusively to the vacuole, while those that include isoform Stv1p are found 
predominantly at the Golgi system and endosomes [59]. In humans, there exist four 
different isoforms for subunit a (a1 to a4). Isoform a1 is found predominantly in synaptic 
vesicles and nerve plasma membrane and is thought to be an important element to facilitate 
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membrane fusion between these two membrane systems [40]. Isoform a2 has been found 
in renal intracellular organelles while isoform a4 is found predominantly in plasma 
membrane-localized V-ATPases in these same cell types [40]. Subunit a3 is found also 
predominantly at the plasma membrane of osteoclasts, although it lies in intracellular 
compartments in non-resorbing cell precursors [60]. To date, the identity of the subunit a 
isoform that drives V-ATPases to acquire a plasma membrane location in tumour cells is 
largely unknown. However, an indication may come from breast cancer MB231 cells. In 
this system, subunits a3 and a4 have been found overexpressed but only the latter isoform 
seems to be responsible for these cells displaying V-ATPases at the plasma membrane 
[61]. 
As mentioned earlier, the stoichiometry of proton translocation is also affected by the 
subunit a isoform included in the holoenzyme. In yeast, Vph1p and Stv1p isoforms provide 
stoichiometries close to 2 and 1 H+/ATP, respectively, in line with the notion that smaller 
ratios of H+/ATP are thought to be helpful for a correct pH homeostasis in non-vacuolar 
yeast compartments [62]. Analogous to this, lemon-fruit vacuolar V-ATPase displays an 
apparently variable stoichiometry with an initial 2H+/ATP ratio that lowers to 1 H+/ATP 
when ΔpH increases across the vacuolar membrane, allowing it to translocate H+ 
effectively even in the presence of steep pH gradients [63]. However, the molecular 
mechanism for these catalytic changes is still unknown. Interestingly, in this same study, it 
was proposed that organic acids could serve as regulators of the V-ATPase improving 
H+/ATP coupling. So far, no studies have dealt with the influence of monocarboxylic acids 
on tumour cell V-ATPase H+ translocation.  
Other regulatory mechanisms may also contribute to fine tune V-ATPase function in a cell. 
For example, it has been described that reduction of disulfide bonds at subunit A are 
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needed for full ATPase activity [64] and that this process may well be at work in vivo [65]. 
Regulation of the number of pumps present in an organelle can also contribute to the 
control of acidification capacity. This  has been observed for epididymal plasma 
membrane ATPases [66], where V-ATPases have been observed to fluctuate between 
plasma membrane and endosomal compartments in a concerted manner depending on 
lumenal pH, cAMP and PKA [67]. Vtc chaperones have also been found to influence 
vacuolar H+-pumping through V-ATPases [68], but in this case a physiological role of Vtc 
complexes in regulating V-ATPase function as a response to environmental or 
physiological cues is less likely. Human securin (hPTTG1 gene) is a protein involved in 
the timely separation of chromatids at anaphase and in promoting proliferation in tumour 
cells [69]. Strikingly, it was also found to be associated to Golgi system and exocytic 
vesicles [70]. Very recently human securin has been proposed as a novel regulator of 
endosomal acidification and membrane traffic [71] apparently through a combination of 
regulation of V-ATPase V0/V1 reversible assembly and gene expression. 
Being V-ATPases membrane-embedded proteins, it is easy to understand that they may be 
affected by the lipid composition of the membrane. However, studies dealing with lipid-
protein interactions for this H+-pump have been few and apart. In any case, a clear 
influence of the lipid environment on V-ATPase functions is starting to emerge. 
Phospholipids and fatty acids have been shown to influence V-ATPase. In particular, 
inclusion of phosphatidylserine in the reconstitution liposomes results in greater ATPase 
activity in vitro [72]. More significantly, rats fed an oleic acid-enriched diet showed an 
accumulation of this fatty acid and a concomitant dramatic increase in both ATPase 
activity and in V1/V0 assembly ratio [73]. Despite lysosomes being sterol-poor organelles 
and endosomes displaying intermediate contents between ER and plasma membrane [74], 
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early studies showed that reconstitution of V-ATPase H+-pumping activity required the 
presence of cholesterol in the liposomes [75]. Related to this, the presence of abnormal 
sterols in the membrane have been shown to have deleterious effects for V-ATPases; for 
example, cellular accumulation of 14α-methylated sterol precursors inhibit fungal V-
ATPase activity [76, 77] and Δ8-unsaturated sterols alter V-ATPase stability (Hernandez, 
A., Lopez-Lluch, G., Serrano-Bueno, G., Perez-Catiñeira, J.R., Navas, P., Serrano, A., 
unpublished data). Sphingolipids are a class of lipids that are often associated to sterols in 
membranes and, along with them, represent the major components of lipid rafts and the 
related detergent resistant membranes (DRMs). Despite V1 being the cytoplasmic domain, 
C26-acyl group containing sphingolipids are necessary to generate ATPase-competent V1 
domains [78]. Other studies have corroborated genetically the importance of sphingolipids 
for V-ATPase function [79]. In mammals, luminal acidification of melanocyte trans-Golgi 
system and endo/lysosomes have been suggested to depend on glycosphingolipids, since a 
cell line devoid of glucosylceramide synthase presents defective luminal acidification [80]. 
Indeed, a regulatory function for lipids in vivo can be envisaged: membrane-bound V-
ATPase subunits were associated with DRMs isolated from late endosomes. Also, the 
V1/V0 assembly ratio varies along the endocytic pathway, the relative abundance of 
membrane-bound V1 being higher on late endosomes than on early endosomes. This 
situation is mimicked by the lipid-raft abundance and the luminal pH in these organelles 
[81]. 
 
CELL BIOLOGY OF V-ATPASE INHIBITION 
As it is easy to foresee, cellular events or processes that require strict or specific pH 
conditions, such as membrane fusion events, may be affected by a fault in V-ATPase H+-
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translocation function. Indeed, inhibition, or otherwise impairment, of H+-translocation by 
V-ATPases provokes a plethora of effects in the cell that, if severe and sustained enough, 
can lead to cell death. A brief overview is depicted on Fig. 3.  
In the context of carbohydrate metabolism, the enzyme fructose-1,6-bisphosphatase is a 
key regulator of gluconeogenesis that is receiving increasing attention in diabetes studies 
[82] . It was observed in yeast that this enzyme is degraded upon shift to glucose 
fermentation metabolism and that this process is V-ATPase dependent, at least after long 
oxidative phosphorylation conditions, since this degradation is done at the vacuole [83]. 
Also in a yeast model system, it was substantiated that vacuolar V-ATPases regulated 
cytosolic pH in concert with the plasma membrane P-type pump [84]. In a cellular breast 
cancer model, silencing of the major V-ATPase subunit a (a3) was also shown to result in 
impaired cytosolic pH homeostasis and a severe drop in invasiveness [61]. It must be 
noted, however, that a concomitant alkalinisation of lumina was also observed in this case, 
making it difficult to ascribe unambiguously the loss of invasive potential to a single 
effect. Examples of the influence of defective V-ATPase-mediated acidification of lumina 
are more abundant in the literature. For instance, impairment of membrane traffic: it was 
shown that yeast cells ablated for any V-ATPase activity missorted Pma1p, the plasma 
membrane P-type proton pump, to the vacuole and, as a consequence, could not alkalinise 
their cytosol in response to glucose [85, 86]. In mammalian cells, a change in 0.4 pH units 
at the Golgi system provokes the mislocalization of glycosyltransferases [14, 15]. A 
similar situation has been observed for secreted proteins like chromogranin [87].  
Another consequence of defective H+-translocation by V-ATPases is the impairement of 
autophagy. This process is intimately associated to cancer, although its exact role, either 
preventing cell death or as a mechanism for it, may differ with cancer type and conditions 
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[88]. It has recently been proposed that the Warburg effect and autophagy may be 
connected in solid tumours, where the core of the neoplasic tissue would be feeding the 
respiration-competent outer tumour cell layers with L-lactate and other nutrients generated 
through anaerobic glycolysis and autophagic degradation of core components [89]. In a 
very simplified view (Fig. 4), this process is characterised by the engulfment of cytosolic 
components and/or other organelles by a double membrane organelle, the phagophore. 
After full closure, the phagophore becomes a cargo loaded double-membrane vesicle, the 
phagosome, this later fuses with endosomes and finally with the lysosome and, after 
degradation of the inner autophagosomal membrane, releases its contents into the 
lysosomal lumen. The engulfed cargo is then degraded by lysosomal proteases and other 
hydrolases [90] . The involvement of the V-ATPase in this process was early observed 
[91] and, nowadays, inhibition of V-ATPase using bafilomycin A1 or concanamycin A is a 
standard assay to probe the involvement of autophagy in mammalian cells. The importance 
of V-ATPases in autophagy is not devoid of controversy, though. In agreement with the 
need of a low luminal pH for vacuole homotypic fusion events, mitophagy (a particular 
form of autophagy dealing with the degradation of whole mitochondria) was seen to be 
affected at the membrane fusion stages. Conversely, those same stages of Piecemeal 
Microautophagy of the Nucleus seems to be independent on V-ATPases [92]. Be that as it 
may, acidification of lysosomal lumen is agreed to be necessary for proteolytic degradation 
of autophagosomal cargo at the lysosome and, together with any effects on membrane 
fusion events, impairment of V-ATPase H+-transport is agreed to block autophagic flow at 
its late steps [93]. At any rate, autophagy is known to be a process that precedes, and thus 
prevents, apoptosis in many instances [94]. Consequently, reports abound on the apoptosis-
inducing effects of the inhibition of autophagy by any means (for example: [95-100]), 
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including the use of bafilomycin A1 (e.g. [101]). However, in this last case a point of 
caution must be exerted since bafilomycin A1 and other plecomacrolides have been seen to 
exert conflicting effects on autophagy and apoptosis induction in neurons depending on the 
concentration used [102]. No data are available on on other cell types or other V-ATPase 
inhibitors, but still the utilisation of plecomacrolides as potentiators of stress or drug-
induced apoptosis through inhibition of autophagy reveals itself as one of the most 
attractive potential uses for V-ATPase inhibiting compounds. 
Many of the chemotherapeutic drugs in present use are cationic molecules. As a 
consequence, they tend to get excluded from alkaline cytosols and accumulate into acidic 
compartments like the lysosome [103]. Not surprisingly then, cells that are able to 
maintain greater pH gradients in these compartments show a greater drug accumulation 
than normal cells [104] and cells showing a greater luminal acidification prowess are more 
chemoresistant than those that do not [105, 106]. Conversely, inhibition of V-ATPase 
activity leads to chemosensitivity [107, 108]. 
Other important effects are those related to iron uptake and Wnt/β-catenin signalling. 
Using global gene expression data Straud et al. found that the increased sensitivity to V-
ATPase inhibitors observed in cancer cells was correlated to their greater dependence on 
iron uptake, presumably to compensate their ROS production [109] . Wnt/ β-catenin 
pathway is an important tumourigenic signal in many cancer cell types, e.g. colorectal 
[110], and ovarian cancers [111]. It has recently been assessed that the Wnt receptor 
complex component LRP6 binds Prorenin receptor as an adaptor to bind V-ATPase. Upon 
activation, LRP6 gets endocytosed and phosphorylated in an acidic environment to become 
active. Furthermore, inhibiton of V-ATPase activity using bafilomycin A1 or apicularen 
prevented Wnt signalling [112]. 
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Cell cycle arrest is a common outcome of V-ATPase inhibition and often preceds cell 
death. S-phase arrest has been reported as a consequence of iejimalide A and B action 
[113], but in general, G1 arrest has been observed. Increased expression of the G1/M 
transition inhibitor p21 has been found in these cases [114-116]. However, the cellular 
mechanisms by which this occurs are not known in detail. In HT-29 colon cancer cells, 
p53 was stabilised following intracellular compartment alkalinization but p21 induction 
was partially p53 independent [114]. On the other hand, G1 arrest was observed to depend 
on inhibition of the degradation of hypoxia-inducible factor 1 (HIF-1) [116]. However, 
the actual mechanism integrating HIF-1 degradation and V-ATPase inhibition is still 
unknown. A hint for this may come from the fact that HIF-1 is a transcription factor that 
induces p21 expression under conditions of hypoxia but that it is kept at low levels under 
normal aeration conditions [117].  
In Hela cells, antisense experiments targeting c proteolipids induced necrosis [118]. 
However, cell death mechanisms related to V-ATPase inhibition in other reports is 
exclusively apoptosis so far [113, 119-123]. Most of these studies have been performed 
using plecomacrolides and, therefore, since there are no data yet for archazolids and 
indoles, and very few in the case of benzolactone enamides, differences may be found in 
future studies. In any case, apoptosis seems to follow the intrinsic pathway of through 
mitochondrial depolarization and liberation of cytochrome c to the cytosol in most 
cases[107, 119, 121] albeit, in EGFR overexpressing cancer cell lines, the extrinsic 
pathway of apoptosis has also been reported to play a decisive role through Fas/FasL in 
concanamycin B-induced cell death [124]. Anyhow, V-ATPase inhibition induced 
apoptosis is probably caspase-dependent in all cases [107, 119, 121]. 
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PHARMACOLOGICAL INHIBITORS OF V-ATPASES 
 
There is a vivid interest in the pharmacological intervention of V-ATPases, since this may 
prove helpful to understand a wide range of diseases, among which is cancer, but that also 
includes osteopetrosis and alzheimer's disease [125, 126]. As a consequence, the list of 
inhibitory compounds identified along the last 30 years is long and heterogeneous. We will 
only review here the most important types, with preference for those commercially 
available, and some strategies that may lead to new approaches towards V-ATPase activity 
regulation. Due to their particular nature, benzimidazole proton pump inhibitors deserve a 
detailed review and thus they will be dealt with in another review article in this issue [Ref 
de Milito]. A more comprehensive list and further details on these and other compounds 
are available in some excellent reviews [127-131].  
 
Plecomacrolides and Derivatives 
 
The first specific inhibitor described for V-ATPases was bafilomycin A1 [132], but 
concanamycin A was first reported that same year [133]. Both compounds are collectively 
known as plecomacrolides and consist of a large macrocyclic lactone ring comprising 16-
18 carbons. Their general structures are shown in Fig. 5. Originally isolated from several 
species of Streptomyces bacteria [129], the total synthesis of bafilomycin A1 was achieved 
in 1997 [134] and that of concanamycin (concanamycin F) in 2001 [135]. Although it is 
now well established that the binding site of both compounds lies on subunit c and that 
causes the inhibition of proton transport through this proteolipid [136], there were some 
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indications that bafilomycin A1 may also bind to subunit a [137] and these have been 
confirmed recently [138]. All of them are very potent inhibitors of V-ATPases with IC50 in 
the low nanomolar range. This makes them useful in research to distinguish between 
different types of ATPases in a cell, since P-type and F0F1-type ATPases are not inhibited 
at concentrations achieving full inhibition of V-ATPases. However, being proteolipid c 
one of the most conserved subunits across species and there being no isoforms in humans, 
the downside is that both bafilomycins and concanamycins lack specificity towards 
different forms of V-ATPases. 
Recently, an unexpected activity of bafilomycin A1 was uncovered: using mitochondria 
isolated from rat liver, bafilomycin A1, in a concentration range between 50 and 250 nM, 
was shown to transport potassium across the inner mitochondrial membrane in a manner 
resembling that of valinomycin, causing swelling and depolarisation independently of any 
inhibition of the F0F1 ATPase [139]. These concentrations are above those needed for 
inhibition of V-ATPases in vitro, but may be meaningful to understand the effects 
observed in in vivo assays. For example, this might help to understand some unresolved 
effects of plecomacrolides, such as the induction of the expression of hypoxia-inducible 
factor 1 (HSF-1) and p21 [115, 116]. Similarly, both concanamycin A and bafilomycin 
A1 have been shown to induce nitric oxide synthase, c-Jun N-terminal kinase and NF-B 
concomitant to mitochondrial swelling and depolarisation in RAW 264.7 leukemia cells 
[140]. 
Using the information obtained in structural studies of bafilomycins, a series of simpler 
compounds that were still able to inhibit V-ATPases were described in the late 1990's 
[141, 142]. These compounds consist of an indole core, hence its name “indoles” (Fig. 5). 
Similarly to plecomacrolides, these compounds also bind subunit c [143, 144]. However, 
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as in the case of the plecomacrolides, it was thought for some time that they may bind to 
subunit a, a situation that could help explaining their preferential inhibition of osteoclast 
V-ATPases, as opposed to other mammalian V-ATPases [141, 142, 145], but this 
hypothesis is now abandoned [146].  
 
Benzolactone Enamides 
 
Compounds sharing a benzolactone enamide core and a cytotoxic profile similar to that of 
plecomacrolides in NCI's 60-Cell screens [147] were identified by two independent groups 
in the late 1990's [148-150]. The first of this, salicylihalamide, was originally isolated from 
Haliclona sp sponges, lobatimides were from Aplidium lobatum tunicates, while 
apicularens were extracted from Chondromyces sp mixobacteria. This wide range of 
sources is probably misleading and chances are that they are all produced by symbiotic 
micro-organisms, most likely mixobacteria [147]. Chemical structures representative of 
this class of compounds are shown on Fig. 6. Total synthesis of these compounds were 
successfully reported a few years later [151-153] and several compounds showing 
similarities have been described, such as cruentaren, the oximidines or the closely related 
palmerolides. An excellent review on these latter compounds was published recently [129]. 
Also similar to plecomacrolides, benzolactone enamides are potent inhibitors of ATP-
dependent H+-translocation showing IC50s in the nanomolar range [129, 154], and bind to 
the V0 domain [136, 154]. However, the binding sites of salicylihalamide and lobatimide 
on the V-ATPase complex are probably different to that of plecomacrolides since the 
former cannot compete binding of the latter type of compounds [136, 154, 155]. 
Interestingly, benzolactone enamides have shown selectivity towards animal V-ATPases, 
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as opposed to their homologous fungal proton pumps [147, 155]. Nevertheless, no 
information is yet available on the exact subunit benzolactone enamides bind. 
 
Alternative Strategies 
 
The major drawback of traditional V-ATPase inhibitors is their lack of cell-type or tissue  
specificity. This comes from a common mechanism of action based at binding V0 domain 
subunits and, in most instances, specifically on the highly conserved c subunit [136, 146, 
154]. Thus, their potential use in cancer chemotherapy is hindered. However, there are 
alternative approaches and molecules that may give some hope. The development of 
systemic delivery methods for gene silencing in vivo may pave the way to effective cancer 
treatment, and this strategy is already being tested for other targets in several types of 
cancer [156]. Gene silencing constructs against tumour-characteristic V-ATPase subunits, 
either delivered systemically or locally, could be effective at circumventing specificity 
issues. At any rate, silencing of single subunits in cell culture models have demonstrated 
its use to reduce tumour cell invasiveness in breast cancer [61]. Moreover, silencing of 
subunit c gene ATP6V0C inhibited dramatically the proliferation and metastatic potential 
of HCCLM3 xenografts in mice liver, albeit gene silencing only reduced expression to 
60% of untreated controls [157]. 
Lipid modulation of V-ATPase activity may provide another alternative way for 
chemotherapeutic intervention. Cancer cells display dramatically increased rates of fatty 
acid synthesis [158], cholesterol uptake and synthesis [159] and dysregulated sphingolipid 
metabolism [160]. This makes them susceptible to pharmacological intervention and its the 
basis of many efforts and proposals (e.g. [161, 162]). Inhibition of any lipid synthesis is 
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inherently pleiotropic; however, from what we have seen above, both sphingolipids and 
sterols seem to be paramount for V-ATPase function [76-79] and own unpublished 
results]. Moreover, abnormal sterol-mediated inhibition of lumenal acidification may well 
lie at the basis of azole fungicide efficacy [77]. Therefore, administration of sphingolipid 
or cholesterol analogues may lead to effective inhibition of V-ATPases. Sphingolipid 
analogues have been tested in cancer models with cytotoxic results in brain, prostate and 
breast cancer. However, these studies did not evaluate the possibility of an induced V-
ATPase dysfunction [160]. LDL receptor-mediated cholesterol uptake mechanisms are 
used to deliver sterol-conjugated compounds into the cell successfully [163]. In addition, 
tumour cells display a dramatic increase in LDL receptors and cholesterol uptake that can 
reach even 100-fold of that found in normal cells [164]. This could be used to increase the 
specificity of V-ATPase inhibition in cancer cells. Indeed several sterol analogues have 
been reported to inhibit V-ATPases in vitro, for example the well known antibiotic fusidic 
acid [165] and the marine sponge metabolites adociasulfates-1, -7 and -8 [166]. 
Nevertheless, no in vivo data are available yet. 
 
CONCLUDING REMARKS 
 
The control of cell proliferation through targeting lumenal, cytosolic and/or extracellular 
pH homeostasis is a strategy that is receiving increasing attention by the scientific 
community and may well prove helpful in the control of cancer progression if sufficient 
effort is put in developing appropriate small molecules. Compounds active against V-
ATPases raise a great interest, as judged by the number of preclinical tests published and 
the fair amount of patents issued [167]. However, V-ATPase inhibitors still face a 
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tremendous challenge to be succesful: their high toxicity. In this sense, inhibition of V-
ATPases in pancreas has been proposed to be responsible of increased risk of suffering 
induced glucose intolerance [168]. Therefore, studies on new derivatives are paramount, 
specially from those compounds that already show some kind of specificity. Alternatively, 
the search for new ways to inhibit V-ATPases, making use of different approaches (e.g. by 
targeting subunit a or by gene silencing) or properties of these proteins that have received 
little attention, like their sensitivity to the lipid environment, may be instrumental in 
regulating V-ATPases, and hence cell proliferation, in the future. 
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Figure Legends 
 
Fig. (1). Intracellular compartments and their internal characteristic pH values. Vesicle 
flux between single membrane organelles is shown by arrows. 
 
Fig. (2). Subunit structure of V-ATPases. Subunits in capital letters constitute the 
hydrophilic V1 domain; subunits in small letters comprise the V0 membrane-embedded 
domain. Asterisks denote the two hemi-channels involved in proton transport. 
 
Fig. (3). Cellular consequences of V-ATPase activity inhibition. Arrow heads indicate 
increase in response while blunt ends indicate diminution in the response. 
 
Fig. (4). Schematic representation of the (macro)autophagic process and autophagosome 
maturation.  
 
Fig. (5). Chemical structure of plecomacrolides and derivatives. A, bafilomycin A; B, 
concanamycin A; C, SB242784 (an indole). 
 
Fig. (6). Chemical structure of benzolactone enamides. A, salicylihalimide A; B, 
lobatamide A; C, apicularen A. 
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